Figure E1.

Virus neutralization against different SARS-CoV-2 variants of concern. Virus neutralization capacity of the subcutaneous immunoglobulin 2 (SCIG#2) product and patient's serum 4 and 20 weeks after immunoglobulin substitution with products containing increasing anti-S-IgG are shown. Data represent mean and SD of three independent experiments. Subcutaneous immunoglobulin 2 shows high neutralization NT₅₀ against the original strain (B.1) and B.1.1.7 (Alpha), and about threefold reduced neutralization against B.1.617.2 (Delta). The patient's serum showed virus neutralization against all three SARS-CoV-2 variants, albeit at lower NT₅₀. In steady-state after 20 weeks, neutralization capacity increased further. However, the newly emerging Omicron variant was only poorly neutralized. Data are derived from three independent experiments. Bars indicate median and range. n/a, respective variant was not tested for the time point; PRNT₅₀, 50% reduction in plaque reduction neutralization test.